EndoChoice released its unaudited, preliminary financial results for the fourth quarter and full year of 2015. The scope maker expects to report $18.6 million in total revenue for the fourth quarter, up from $18.3 million in the fourth quarter of 2014.
EndoChoice entered into a distribution agreement with Chindex Medical.
Cologuard, Exact Sciences‘ stool DNA based colorectal cancer screen test, has new modeling data supporting a three-year testing interval.
More than 100,000 Cologuard tests were completed by the end of 2015, but Exact Sciences expects the number of its stool DNA-based colorectal cancer screening tests completed in 2016 will more than double.
SonarMD, a web-based application designed to allow physicians to monitor Crohn’s disease patients’ health status between in-person visits, has formed a partnership with Digestive Healthcare Center of New Jersey in Hillsborough Township.
Takeda Pharmaceutical and enGene, a privately held biotechnology company, announced a new strategic alliance. Through the alliance, the company aims to develop and commercialize novel therapies for specialty gastrointestinal diseases using enGene’s gene delivery platform, Gene Pill.
VolitionRX, a developer of blood tests that can predict colon cancer, is looking to start selling the blood test system in the United States in the next year.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.
More articles on gastroenterology:
FDA clears 51 GI/endoscopy devices in 2015
5 most-read GI/endoscopy stories: Week of Jan. 4 – Jan. 8
Dr. Sandra Jara joins Gastroenterology Group of Naples
